Nicola Gökbuget, MD - Achieving Therapeutic Innovation in ALL: Insights on Modern Asparaginase Compounds in Pediatric, AYA, and Adult Patients

1:23:31
 
Share
 

Manage episode 299335818 series 103624
By PeerView Press, 24 West 40th Street, Suite 950, New York, NY 10018, PVI, and PeerView Institute for Medical Education. Discovered by Player FM and our community — copyright is owned by the publisher, not Player FM, and audio is streamed directly from their servers. Hit the Subscribe button to track updates in Player FM, or paste the feed URL into other podcast apps.
Go online to PeerView.com/JPA860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. This Clinical Consults activity features case-based expert discussions on the use of asparaginase in the context of broader innovations in ALL care across pediatric, AYA, and adult patients. Our experts give insights on standard asparaginase compounds, monitoring and management of toxicities, hypersensitivity/silent inactivation, and sequential use of alternative asparaginase compounds. Upon completion of this accredited CE activity, participants should be better able to: Cite current, multimodal recommendations for acute lymphoblastic leukemia (ALL) management in pediatric, adolescents and young adult (AYA), and adult populations, including multi-agent chemotherapy and asparaginase compounds, antibody-based approaches, cellular therapy, and tyrosine kinase inhibitors, Discuss the clinical implications of Escherichia coli (E. coli) asparaginase hypersensitivity and asparaginase discontinuation in ALL, including in pediatric, AYA, and adult populations, Summarize evidence surrounding the use of Erwinia chrysanthemi asparaginase, including recombinant formulations as a component of chemotherapy for ALL, Apply updated protocols for the management of E. coli asparaginase hypersensitivity, including monitoring and strategies for switching to Erwinia asparaginase options.

298 episodes